vs

Side-by-side financial comparison of Oncology Institute, Inc. (TOI) and TRIMAS CORP (TRS). Click either name above to swap in a different company.

TRIMAS CORP is the larger business by last-quarter revenue ($256.5M vs $142.0M, roughly 1.8× Oncology Institute, Inc.). TRIMAS CORP runs the higher net margin — 31.9% vs -5.3%, a 37.1% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs 3.8%). TRIMAS CORP produced more free cash flow last quarter ($36.8M vs $2.2M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs 3.3%).

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.

TOI vs TRS — Head-to-Head

Bigger by revenue
TRS
TRS
1.8× larger
TRS
$256.5M
$142.0M
TOI
Growing faster (revenue YoY)
TOI
TOI
+37.7% gap
TOI
41.6%
3.8%
TRS
Higher net margin
TRS
TRS
37.1% more per $
TRS
31.9%
-5.3%
TOI
More free cash flow
TRS
TRS
$34.6M more FCF
TRS
$36.8M
$2.2M
TOI
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
3.3%
TRS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
TOI
TOI
TRS
TRS
Revenue
$142.0M
$256.5M
Net Profit
$-7.5M
$81.7M
Gross Margin
12.8%
Operating Margin
-4.9%
5.7%
Net Margin
-5.3%
31.9%
Revenue YoY
41.6%
3.8%
Net Profit YoY
43.0%
236.9%
EPS (diluted)
$-0.04
$2.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TOI
TOI
TRS
TRS
Q1 26
$256.5M
Q4 25
$142.0M
$-140.0M
Q3 25
$136.6M
$269.3M
Q2 25
$119.8M
$274.8M
Q1 25
$104.4M
$241.7M
Q4 24
$100.3M
$-66.2M
Q3 24
$99.9M
$229.4M
Q2 24
$98.6M
$240.5M
Net Profit
TOI
TOI
TRS
TRS
Q1 26
$81.7M
Q4 25
$-7.5M
$81.7M
Q3 25
$-16.5M
$9.3M
Q2 25
$-17.0M
$16.7M
Q1 25
$-19.6M
$12.4M
Q4 24
$-13.2M
$5.6M
Q3 24
$-16.1M
$2.5M
Q2 24
$-15.5M
$10.9M
Gross Margin
TOI
TOI
TRS
TRS
Q1 26
12.8%
Q4 25
Q3 25
12.8%
Q2 25
13.8%
Q1 25
13.6%
Q4 24
Q3 24
15.4%
Q2 24
14.4%
Operating Margin
TOI
TOI
TRS
TRS
Q1 26
5.7%
Q4 25
-4.9%
Q3 25
-5.9%
6.2%
Q2 25
-9.4%
9.9%
Q1 25
-9.5%
9.0%
Q4 24
-11.9%
Q3 24
-13.9%
3.6%
Q2 24
-16.6%
7.4%
Net Margin
TOI
TOI
TRS
TRS
Q1 26
31.9%
Q4 25
-5.3%
-58.4%
Q3 25
-12.1%
3.5%
Q2 25
-14.2%
6.1%
Q1 25
-18.8%
5.1%
Q4 24
-13.1%
-8.5%
Q3 24
-16.1%
1.1%
Q2 24
-15.7%
4.5%
EPS (diluted)
TOI
TOI
TRS
TRS
Q1 26
$2.03
Q4 25
$-0.04
$2.01
Q3 25
$-0.14
$0.23
Q2 25
$-0.15
$0.41
Q1 25
$-0.21
$0.30
Q4 24
$-0.14
$0.14
Q3 24
$-0.18
$0.06
Q2 24
$-0.17
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TOI
TOI
TRS
TRS
Cash + ST InvestmentsLiquidity on hand
$30.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-15.7M
$705.6M
Total Assets
$164.7M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TOI
TOI
TRS
TRS
Q1 26
$30.0M
Q4 25
$30.0M
Q3 25
$33.6M
Q2 25
$30.3M
Q1 25
$32.7M
Q4 24
$23.1M
Q3 24
$26.9M
Q2 24
$9.9M
$35.0M
Total Debt
TOI
TOI
TRS
TRS
Q1 26
Q4 25
$469.2M
Q3 25
$407.1M
Q2 25
$424.5M
Q1 25
$434.2M
Q4 24
$398.1M
Q3 24
$409.9M
Q2 24
$427.4M
Stockholders' Equity
TOI
TOI
TRS
TRS
Q1 26
$705.6M
Q4 25
$-15.7M
$705.6M
Q3 25
$-12.3M
$725.0M
Q2 25
$-9.0M
$715.3M
Q1 25
$5.1M
$686.6M
Q4 24
$3.6M
$667.3M
Q3 24
$15.5M
$682.8M
Q2 24
$29.2M
$675.9M
Total Assets
TOI
TOI
TRS
TRS
Q1 26
$1.5B
Q4 25
$164.7M
$1.5B
Q3 25
$163.6M
$1.4B
Q2 25
$159.8M
$1.4B
Q1 25
$164.0M
$1.4B
Q4 24
$172.7M
$1.3B
Q3 24
$179.2M
$1.4B
Q2 24
$179.6M
$1.4B
Debt / Equity
TOI
TOI
TRS
TRS
Q1 26
Q4 25
0.66×
Q3 25
0.56×
Q2 25
0.59×
Q1 25
0.63×
Q4 24
0.60×
Q3 24
0.60×
Q2 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TOI
TOI
TRS
TRS
Operating Cash FlowLast quarter
$3.2M
$117.5M
Free Cash FlowOCF − Capex
$2.2M
$36.8M
FCF MarginFCF / Revenue
1.5%
14.4%
Capex IntensityCapex / Revenue
0.7%
18.9%
Cash ConversionOCF / Net Profit
1.44×
TTM Free Cash FlowTrailing 4 quarters
$-27.8M
$109.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TOI
TOI
TRS
TRS
Q1 26
$117.5M
Q4 25
$3.2M
$41.5M
Q3 25
$-12.6M
$36.5M
Q2 25
$-10.2M
$30.3M
Q1 25
$-5.0M
$9.2M
Q4 24
$4.2M
$27.1M
Q3 24
$819.0K
$22.0M
Q2 24
$-15.7M
$18.4M
Free Cash Flow
TOI
TOI
TRS
TRS
Q1 26
$36.8M
Q4 25
$2.2M
$36.8M
Q3 25
$-13.2M
$22.8M
Q2 25
$-11.4M
$13.2M
Q1 25
$-5.3M
$-3.8M
Q4 24
$2.4M
$12.1M
Q3 24
$417.0K
$10.2M
Q2 24
$-17.5M
$7.5M
FCF Margin
TOI
TOI
TRS
TRS
Q1 26
14.4%
Q4 25
1.5%
-26.3%
Q3 25
-9.7%
8.5%
Q2 25
-9.5%
4.8%
Q1 25
-5.1%
-1.6%
Q4 24
2.4%
-18.3%
Q3 24
0.4%
4.4%
Q2 24
-17.7%
3.1%
Capex Intensity
TOI
TOI
TRS
TRS
Q1 26
18.9%
Q4 25
0.7%
-3.4%
Q3 25
0.4%
5.1%
Q2 25
1.0%
6.2%
Q1 25
0.3%
5.4%
Q4 24
1.8%
-22.6%
Q3 24
0.4%
5.2%
Q2 24
1.9%
4.5%
Cash Conversion
TOI
TOI
TRS
TRS
Q1 26
1.44×
Q4 25
0.51×
Q3 25
3.92×
Q2 25
1.81×
Q1 25
0.74×
Q4 24
4.80×
Q3 24
8.71×
Q2 24
1.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

TRS
TRS

Segment breakdown not available.

Related Comparisons